MarketPulse

hypercortisolism

6 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Corcept Therapeutics Hit With Class Action Suit After FDA Rejection Triggers 50% Stock Plunge

Pomerantz Law Firm files class action lawsuit against $CORT after FDA rejection of relacorilant causes 50.4% stock decline. Investors urged to act by April 21, 2026 deadline.
CORTEOSENKTRsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Corcept Therapeutics Faces Securities Lawsuit Over Alleged Drug Trial Misrepresentations

Rosen Law Firm pursues class action against $CORT for allegedly misrepresenting relacorilant clinical trial data and FDA communications. Lead plaintiff deadline: April 21, 2026.
CORTENPHCIGLsecurities class actionrelacorilant
GlobeNewswire Inc.GlobeNewswire Inc.··Glancy Prongay Wolke & Rotter Llp

CORT Stock Plunges 50% on FDA Rejection; Securities Fraud Lawsuit Filed

Corcept Therapeutics shares crashed 50% after FDA rejected relacorilant application. Class action lawsuit alleges company concealed prior FDA warnings about clinical development concerns.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kirby Mcinerney Llp

Corcept Stock Tanks 50% After FDA Rejection, Class Action Lawsuit Filed

Corcept Therapeutics faces class action lawsuit for allegedly misrepresenting FDA trial data; stock collapsed 50% after regulatory rejection of relacorilant drug.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Glancy Prongay Wolke & Rotter Llp

CORT Plunges 50% After FDA Rejection; Securities Fraud Lawsuit Filed

Corcept Therapeutics faces class action lawsuit after FDA rejected relacorilant drug application, triggering 50% stock collapse and disclosure allegations.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Levi & Korsinsky, Llp

Corcept Therapeutics Hit with Class Action Over FDA Drug Study Misrepresentations

Law firm files securities lawsuit against $CORT alleging false statements about FDA interactions regarding relacorilant drug approval prospects.
CORTsecurities fraudclass action lawsuit